Qualitative interviews with 43 patients on capivasertib plus fulvestrant found the 4-on/3-off dosing schedule broadly acceptable, while identifying gaps in hyperglycemia recognition and willingness to use supportive medications.
Emily Mulvihill
Advertisement
Articles by Emily Mulvihill
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Revolutionizing Oncology in the Digital Age: Effects on Health Care Providers
2
How Do You Choose The Right Frontline Therapy in CLL Care?
3
3 Things You Should Know About Using Selective Estrogen Receptor Degraders in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
4
3 Things You Should Know About Frontline and Maintenance Therapy for HER2+ Metastatic Breast Cancer
5